New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting

被引：0
作者：
Matthieu Roulleaux-Dugage
Antoine Italiano
机构：
[1] Institut Bergonié,Department of Medicine
[2] Gustave Roussy,DITEP
[3] University of Bordeaux,Faculty of Medicine
来源：
Journal of Hematology & Oncology | / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immunotherapy could be an effective therapeutic strategy for this group of diseases. Here, we reviewed the latest advances of immunotherapy trials from the 2023 American Society of Clinical Oncology Annual Meeting, including some novel and encouraging combination regimens. Further research is still needed to fully understand the optimal use of these agents in sarcoma treatment.
引用
收藏
相关论文
共 225 条
  • [1] Italiano A(2020)PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials J Hematol Oncol 13 55-262
  • [2] Bellera C(2013)Role of macrophage targeting in the antitumor activity of trabectedin Cancer Cell 23 249-5161
  • [3] D’Angelo S(2017)Trabectedin overrides osteosarcoma differentiative block and reprograms the tumor immune environment enabling effective combination with immune checkpoint inhibitors Clin Cancer Res 23 5149-426
  • [4] Germano G(2014)Consensus guidelines for the detection of immunogenic cell death Oncoimmunology 3 416-6667
  • [5] Frapolli R(2018)Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials Lancet Oncol 19 6662-61
  • [6] Belgiovine C(2017)Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies Oncoimmunology 7 54-82
  • [7] Anselmo A(2012)The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors Proc Natl Acad Sci USA 109 69-1501
  • [8] Pesce S(2007)Calreticulin exposure dictates the immunogenicity of cancer cell death Nat Med 13 1493-1206
  • [9] Liguori M(2018)Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy Breast Cancer Res Treat 172 11579-undefined
  • [10] Ratti C(2017)Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial Lancet Oncol 18 1199-undefined
12345678910